- Home
- FTDR vs CRNX Comparison
FTDR vs CRNX Comparison
Compare FTDR & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTDR | CRNX |
|---|---|---|
| Founded | 1971 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.9B |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | FTDR | CRNX |
|---|---|---|
| Price | $75.14 | $83.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $67.20 | ★ $76.75 |
| AVG Volume (30 Days) | 696.2K | ★ 5.2M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.62 | N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $2,093,000,000.00 | $1,039,000.00 |
| Revenue This Year | $5.97 | $720.10 |
| Revenue Next Year | $5.82 | $184.67 |
| P/E Ratio | $133.61 | ★ N/A |
| Revenue Growth | ★ 13.56 | N/A |
| 52 Week Low | $48.47 | $25.83 |
| 52 Week High | $80.73 | $83.70 |
Technical Indicators
Market Signals| Indicator | FTDR | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 58.77 | 93.09 |
| Support Level | $55.98 | $41.42 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 2.71 | 1.38 |
| MACD | -0.27 | 5.72 |
| Stochastic Oscillator | 41.62 | 99.72 |
Price Performance
Historical ComparisonAbout FTDR Frontdoor Inc.
Frontdoor Inc is a United States-based company that provides home service plans. It owns multiple home service brands including American Home Shield, HSA, OneGuard, and Landmark brands. Through its home service plans, the company helps its customers maintain their homes and protect against costly and unexpected breakdowns of essential home systems and appliances.
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.